2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Conditions
Liver Failure
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Oxaliplatin
1439
Fluorouracil
1319
Capecitabine
1114
Gemcitabine
1057
Leucovorin
939
Bevacizumab
847
Irinotecan
830
Cisplatin
676
Radiotherapy
560
Cetuximab
482
pembrolizumab
435
Paclitaxel
401
Drug Therapy
358
Nivolumab
350
130-nm albumin-bound paclitaxel
328
Docetaxel
290
Sorafenib
288
S 1 (combination)
279
Folfox protocol
266
Albumin-Bound Paclitaxel
263
Surgical Procedures, Operative
257
lenvatinib
222
sintilimab
218
tislelizumab
214
durvalumab
212
regorafenib
209
Magnetic Resonance Spectroscopy
205
apatinib
204
Radiosurgery
204
Neoadjuvant Therapy
190
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Raltegravir Potassium
×
Gastrointestinal
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled